AUDENTES THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
AUDENTES THERAPEUTICS INC. - More news...
AUDENTES THERAPEUTICS INC. - More news...
- Astellas Completes Acquisition of Audentes Therapeutics
- SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Audentes Therapeutics, Inc. - BOLD
- SHAREHOLDER ALERT: WeissLaw LLP Investigates Audentes Therapeutics, Inc.
- AUDENTES ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of BOLD and Encourages Investors to Contact the Firm
- Audentes Therapeutics Presents New Positive Data from ASPIRO, the Clinical Trial Evaluating AT132 in Patients with X-Linked Myotubular Myopathy (XLMTM), at the 24th International Annual Congress of the World Muscle Society
- Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Audentes Therapeutics to Participate in Upcoming Investor Conferences
- Audentes Announces Upcoming Presentations at the 24th International Annual Congress of the World Muscle Society, Including New Data From ASPIRO, the Clinical Trial Evaluating AT132 in Patients With X-Linked Myotubular Myopathy (XLMTM)
- Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Audentes Therapeutics to Participate in Upcoming Investor Conferences
- Audentes Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
- Audentes Therapeutics to Participate in Upcoming Investor Conferences
- Audentes Therapeutics to Release Second Quarter 2019 Financial Results and Provide Corporate Update on Tuesday, August 6, 2019
- Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Audentes Therapeutics Announces Changes to Senior Management Team
- Audentes Therapeutics to Participate in the Bank of America Merrill Lynch 2019 Health Care Conference
- Audentes Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
- Audentes Therapeutics Presents New Positive Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 for X-linked Myotubular Myopathy, at 22nd Annual Meeting of the American Society of Gene and Cell Therapy
- Audentes Therapeutics to Release First Quarter 2019 Financial Results and Provide Corporate Update on Tuesday, May 7, 2019
- Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Audentes Therapeutics Announces Launch of New State-of-the-Art Internal cGMP Plasmid Manufacturing Facility
- Audentes Therapeutics Announces Upcoming Presentations at 22nd Annual Meeting of the American Society of Gene and Cell Therapy Including New Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy
- Audentes Therapeutics Announces Expansion of AAV Technology Platform and Pipeline with New Development Programs for Duchenne Muscular Dystrophy and Myotonic Dystrophy
- Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Audentes Therapeutics Appoints Legal and Corporate Communications Executives; Promotes Thomas P. Soloway to Executive Vice President and Chief Financial Officer
- Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Audentes Therapeutics Recognizes Rare Disease Day by Launching "Be Bold for Courageous Patients" Program to Support Patients Living with Rare Diseases
- Audentes Therapeutics Reports Fourth Quarter 2018 and Full Year Financial Results and Provides Corporate Update
- Audentes Therapeutics to Release Fourth Quarter and Full Year 2018 Financial Results and Provide Corporate Update on Wednesday, February 27, 2019
